2030年に53.3兆円のバイオものづくり市場へ。政府戦略が自ら挙げる最大の壁はコスト
2024年改訂のバイオエコノミー戦略は、五つの市場ごとに2030年目標を置き、バイオものづくりを53.3兆円とした。戦略自身が難しさの理由を明記している。バイオ由来品は代替する化石由来の化学品よりコストが高く、市場に委ねたままでは需要が読めない。
On 3 June 2024 Japan’s Integrated Innovation Strategy Promotion Council issued a revised Bioeconomy Strategy, replacing the 2019 version that had set the goal of “realizing the world’s most advanced bioeconomy society by 2030” (Cabinet Office).
Most coverage of it reported the headline: markets “in the order of 100 trillion yen in Japan and abroad by 2030.” The more useful part of the document is further in, where the 2019 strategy’s nine markets are consolidated into five, and each of the five is given its own 2030 target market size.
The five numbers
| Market | 2030 target market size |
|---|---|
| Biomanufacturing and bio-derived products | ¥53.3 trillion |
| Sustainable primary production systems | up to ¥14.9 trillion (¥1.7T domestic, ¥13.2T overseas) |
| Large-scale buildings using wood, and smart forestry | ¥1.0 trillion (domestic) |
| Biopharmaceuticals, regenerative medicine, cell and gene therapies | up to ¥58.6 trillion (¥3.3T domestic, ¥55.3T overseas) |
| Lifestyle improvement healthcare and digital health | ¥39.1 trillion |
All five figures are from the strategy’s own “Goals for the year 2030” sections (Cabinet Office).
Two things stand out before any analysis. The five targets add up to considerably more than the ¥100 trillion headline, and two of them are stated as “up to” figures that mix domestic and overseas market share. Our reading is that they were not built to sum — each is a target for a market Japanese firms compete in, not a slice of one pie. Anyone modelling off this document should treat the domain figures as the substantive ones and the ¥100 trillion as framing.
The second is the split inside the biopharma line. Of its ¥58.6 trillion, ¥55.3 trillion is overseas and ¥3.3 trillion domestic. Japan’s largest single bioeconomy target is, on its own arithmetic, an export target. Biomanufacturing’s ¥53.3 trillion carries no domestic-overseas split at all.
The number that is a commitment rather than a forecast
Market-size targets are forecasts dressed as goals. Underneath the biomanufacturing target sit two indices that are not:
- raise combined government and private investment in biomanufacturing to ¥3 trillion per year by 2030;
- introduce approximately 2 million tonnes of bioplastics by 2030, under the Roadmap for Bioplastics Introduction.
Those are the lines to track. Japan already has a base to build from: in fiscal 2022 it started full-scale national projects with a budget “in the order of 1 trillion yen in total to biomanufacturing and other fields of biotechnology” (Cabinet Office). Getting from that to ¥3 trillion a year, most of it private, is the actual bet.
The strategy says out loud that Japan started late
Industrial strategy documents rarely concede position. This one does, in the section on future efforts for biomanufacturing:
“While the biomanufacturing area has seen intensifying international competitions, such as large-scale investments already made in the U.S. and China ahead of Japan, it is still a new area with immature markets without dominant players.”
The strategy is explicit about what prompted the revision. In September 2022 the US signed the Executive Order on Advancing Biotechnology and Biomanufacturing Innovation and announced the National Biotechnology and Biomanufacturing Initiative; the accompanying US analysis predicted biomanufacturing would replace one-third of global manufacturing output within ten years, which it valued at roughly US$30 trillion. Japan’s document reproduces that figure, converted at ¥140/USD, and follows it with Europe’s regulatory route — the December 2023 amendment to the Renewable Energy Directive, RED III — as a contrasting model built around a circular bioeconomy.
Having conceded the gap, the strategy names where Japan intends to compete rather than claiming breadth. It points at microorganism and cell design platforms, at hosts “that are likely to give us advantages, such as hydrogen-oxidizing bacteria,” and at “culture, fermentation, and other production processes that have long been worked on in Japan.” That is a narrower and more defensible claim than most national bioeconomy plans make.
The constraint the document refuses to hide
The most valuable paragraphs in the strategy are the ones about cost. On bio-derived products:
“the greatest challenge in creating and expanding markets of bio-derived products is cost competitiveness. When a more cost-competitive, fossil resource-derived product produced by chemical process is substituted by a bio-derived product, the process cost is expected to increase due to reduced productivity or other causes, in addition to having to make a new capital investment.”
And then the conclusion that follows from it:
“In this situation where the added values of bio-derived products have not sufficiently appealed to demanders, we cannot forecast demand for bio-derived products if the market is left solely up to market principles.”
A government writing that its own target market will not appear on market principles alone is telling you where policy has to go next. The strategy’s answer is to “advance the improvement of the market environment” and increase market predictability for businesses — the vocabulary of demand-side intervention: procurement, mandates, standards, offtake certainty.
This is the same structural problem Japan is working in green steel, where the technology exists and the cost premium is what stops it moving, and the same one that advance market commitments are designed to solve in other sectors. Readers following those threads may find our earlier briefings on Japan’s demand-side green steel problem and on advance market commitments as impact capital useful alongside this one.
What it means if you are building or funding here
Three practical readings.
The policy signal to watch is demand, not R&D. Japan has already put roughly a trillion yen through research and translation programmes. The strategy’s own diagnosis is that the binding constraint has moved downstream to price and demand certainty. If the next set of measures is more grant funding, the ¥53.3 trillion target has not been resourced against the problem the document itself identifies. If it is procurement rules, bioplastics content requirements or long-term offtake support, it has.
Bioplastics is the near-term proving ground. It is the only sub-market in the biomanufacturing section with a physical volume target — about 2 million tonnes by 2030 — and the strategy notes its social implementation is already under way. Volume targets are auditable in a way that yen-denominated market forecasts are not.
Feedstock is treated as a security question, not only a cost question. The strategy repeatedly links biomanufacturing to Japan’s reliance on overseas suppliers for raw materials, and directs effort at “the utilization of unused resources” domestically, under the Basic Plan for Promoting Biomass Utilization. Founders whose process runs on imported feedstock are solving a different problem from the one Japanese policy is trying to solve.
None of this makes the ¥53.3 trillion figure a prediction. It is a target, published by a government that has written down why reaching it is hard and where it is behind. That combination — a large stated ambition, a candid constraint, and no dominant incumbent — is the condition under which capital and technology tend to move fastest, and it is worth reading the original document rather than the headline.
The Tech for Impact Summit is an invitation-only executive gathering that brings together senior leaders across business, policy and culture to move high-impact technology from strategy to deployment. T4IS2027 takes place in Tokyo on May 18–19, 2027. If the questions in this briefing are the ones your organisation is working on, you can join the waitlist and we will be in touch.